GSK to Acquire Nuvalent in Largest Deal in Over a Decade – Merger Arbitrage Mondays

Nuvalent, Inc. (NUVL): $123.25

Market Cap: $9.07 B

Deal Value: $9.4 B

British pharma giant GSK plc (GSK) entered into a definitive merger agreement on June 9, 2026, to acquire oncology drug developer Nuvalent in a cash deal valued at $9.4 billion, its largest in over a decade.

GSK will commence a tender offer within 10 business days to acquire all of Nuvalent’s outstanding Class A and Class B common stock for $124 per share in cash, representing a 40.13% premium to the stock’s last closing price.

Only plus or premium subscribers can access this post. Subscribe today.